Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant mesothelioma. Intern Med J. 2010;40(11):742–50. https://doi.org/10.1111/j.1445-5994.2010.02223.x.

Article  PubMed  Google Scholar 

Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, Lin X, Lucero-Prisno DE 3rd, Xu W, Zheng ZJ, Elcarte E, Withers M, Wong MCS, NCD Global Health Research Group, Association of Pacific Rim Universities (APRU). Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18(6):792–802. https://doi.org/10.1016/j.jtho.2023.01.095.

Article  PubMed  Google Scholar 

Royal College of Physicians. National mesothelioma audit report 2020 (Audit Period 2016–18). London: RCP; 2020.

Google Scholar 

Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, Lima VCC. Malignant pleural mesothelioma: an update. J Bras Pneumol. 2021;47(6): e20210129. https://doi.org/10.36416/1806-3756/e20210129.

Article  PubMed  PubMed Central  Google Scholar 

Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17(8):475–88. https://doi.org/10.1038/nrc.2017.42.

Article  CAS  PubMed  Google Scholar 

Pairman L, Beckert LEL, Dagger M, Maze MJ. Evaluation of pleural fluid cytology for the diagnosis of malignant pleural effusion: a retrospective cohort study. Intern Med J. 2022;52(7):1154–9. https://doi.org/10.1111/imj.15725.

Article  PubMed  PubMed Central  Google Scholar 

WHO Classification of Tumours Editorial Board. Thoracic Tumours. 5th ed. Lyon, France: International Agency for Research on Cancer; 2020.

Google Scholar 

Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, et al. Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743–50.

Article  PubMed  PubMed Central  Google Scholar 

• Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2022 Feb;33(2):129–142. https://doi.org/10.1016/j.annonc.2021.11.005. This reference is of outstanding importance as it is a recent guideline published by the European Society of Medical Oncology (ESMO) on the management of MPM.

Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Pass H, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, IASLC Staging Committee. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631–9. https://doi.org/10.1097/JTO.0b013e31826915f1.

Article  PubMed  Google Scholar 

Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O’Brien M, Thomas G, Senan S, O’Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J, MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72. https://doi.org/10.1016/S1470-2045(11)70149-8.

Article  PubMed  PubMed Central  Google Scholar 

Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5. https://doi.org/10.1016/j.lungcan.2013.11.026.

Article  PubMed  Google Scholar 

Taioli E, Wolf AS, Flores RM. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472–80. https://doi.org/10.1016/j.athoracsur.2014.09.056.

Article  PubMed  Google Scholar 

Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S, Rintoul RC, Waller D, Ali C, Bille A, Fuller L, Ionescu A, Keni M, Kirk A, Koh P, Lau K, Mansy T, Maskell NA, Milton R, Muthukumar D, Pope T, Roy A, Shah R, Shamash J, Tasigiannopoulos Z, Taylor P, Treece S, Ashton K, Harris R, Joyce K, Warnes B, Mills N, Stokes EA, Rogers C, MARS 2 Trialists. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020;10(9):e038892. https://doi.org/10.1136/bmjopen-2020-038892.

Article  PubMed  PubMed Central  Google Scholar 

Raskin J, Surmont V, Cornelissen R, Baas P, van Schil PEY, van Meerbeeck JP. A randomized phase 2 study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Transl Lung Cancer Res. 2018;7(5):593–8. https://doi.org/10.21037/tlcr.2018.05.07.

Article  PubMed  PubMed Central  Google Scholar 

Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, Lovato E, Hughes V, Fox-Rushby JA, Sharples LD, MesoVATS Collaborators. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–27. https://doi.org/10.1016/S0140-6736(14)60418-9.

Article  PubMed  Google Scholar 

Matthews C, Freeman C, Sharples LD, Fox-Rushby J, Tod A, Maskell NA, Edwards JG, Coonar AS, Sivasothy P, Hughes V, Rahman NM, Waller DA, Rintoul RC. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase 3 trial. BMJ Open Respir Res. 2019;6(1): e000368. https://doi.org/10.1136/bmjresp-2018-000368.

Article  PubMed  PubMed Central  Google Scholar 

Bydder S, Phillips M, Joseph DJ, Cameron F, Spry NA, DeMelker Y, Musk AW. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9–10. https://doi.org/10.1038/sj.bjc.6601957.

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Rourke N, Garcia JC, Paul J, Lawless C, McMenemin R, Hill J. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18–22. https://doi.org/10.1016/j.radonc.2007.05.022.

Article  PubMed  Google Scholar 

Clive AO, Taylor H, Dobson L, Wilson P, de Winton E, Panakis N, Pepperell J, Howell T, Stewart SA, Penz E, Jordan N, Morley AJ, Zahan-Evans N, Smith S, Batchelor TJP, Marchbank A, Bishop L, Ionescu AA, Bayne M, Cooper S, Kerry A, Jenkins P, Toy E, Vigneswaran V, Gildersleve J, Ahmed M, McDonald F, Button M, Lewanski C, Comins C, Dakshinamoorthy M, Lee YCG, Rahman NM, Maskell NA. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094–104. https://doi.org/10.1016/S1470-2045(16)30095-X.

Article  PubMed  PubMed Central  Google Scholar 

Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, Edwards JG, Ezhil V, Gilligan D, Hatton M, Jegannathen A, Mansy T, Peake MD, Pemberton L, Rintoul RC, Snee M, Ryder WD, Taylor P, Faivre-Finn C. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase 3 randomized trial. J Clin Oncol. 2019;37(14):1200–8. https://doi.org/10.1200/JCO.18.01678.

Article  CAS  PubMed  Google Scholar 

Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343–73. https://doi.org/10.1200/JCO.2017.76.6394.

Article  PubMed  Google Scholar 

Macleod N, Price A, O’Rourke N, Fallon M, Laird B. Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review. Lung Cancer. 2014;83(2):133–8. https://doi.org/10.1016/j.lungcan.2013.11.004.

Article  CAS  PubMed  Google Scholar 

MacLeod N, Chalmers A, O’Rourke N, Moore K, Sheridan J, McMahon L, Bray C, Stobo J, Price A, Fallon M, Laird BJ. Is radiotherapy useful for treating pain in mesothelioma?: A Phase 2 Trial. J Thorac Oncol. 2015;10(6):944–50. https://doi.org/10.1097/JTO.0000000000000499.

Article  PubMed  Google Scholar 

Ashton M, O'Rourke N, Macleod N, Laird B, Stobo J, Kelly C, Alexander L, Franks K, Moore K, Currie S, Valentine R, Chalmers AJ. SYSTEMS-2: a randomised phase 2 study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. Lung Cancer. 2023 Apr; 168 (Supplement 1, S22-S23). Abstract only. https://doi.org/10.1016/S0169-5002(23)00477-4

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651–8. https://doi.org/10.1016/S1470-2045(15)00208-9.

Article  PubMed  Google Scholar 

Cho BCJ, Donahoe L, Bradbury PA, Leighl N, Keshavjee S, Hope A, Pal P, Cabanero M, Czarnecka K, McRae K, Tsao MS, de Perrot M. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. Lancet Oncol. 2021;22(2):190–7. https://doi.org/10.1016/S1470-2045(20)30606-9.

Article  PubMed  Google Scholar 

Chen Z, Dominello MM, Joiner MC, Burmeister JW. Proton versus photon radiation therapy: a clinical review. Front Oncol. 2023;29(13):1133909. https://doi.org/10.3389/fonc.2023.1133909.

Article  Google Scholar 

Tsao AS, Pass HI, Rimner A, Mansfield AS. New era for malignant pleural mesothelioma: updates on therapeutic options. J Clin Oncol. 2022;40(6):681–92. https://doi.org/10.1200/JCO.21.01567.

Article  PubMed  PubMed Central  Google Scholar 

Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res. 2023;29(3):548–59. https://doi.org/10.1158/1078-0432.CCR-22-2566.

Article  CAS  PubMed  Google Scholar 

Cui W, Popat S. Pleural mesothelioma (PM) - the status of systemic therapy. Cancer Treat Rev. 2021;100: 102265. https://doi.org/10.1016/j.ctrv.2021.102265.

Article  CAS  PubMed  Google Scholar 

• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase 3 study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. doi: https://doi.org/10.1200/JCO.2003.11.136. Corrected and republished in: J Clin Oncol. 2023 Apr 20;41(12):2125–2133. This reference is of importance as it is a phase 3 study establishing the role of doublet chemotherapy in standard of care first line management of MPM.

van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase 3 study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9. https://doi.org/10.1200/JCO.20005.14.589.